Risk factors for cardiogenic shock in thyroid storm: a retrospective and case-series study.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Future cardiology Pub Date : 2023-09-01 Epub Date: 2023-10-13 DOI:10.2217/fca-2023-0043

Kevin Pink, Aaron C Yee, Edward T Ha, Maxim Kashin, Benjamin Berson, Stephen J Peterson, Shudhanshu Alishetti, Wilbert Aronow, Kumudha Ramasubbu

引用次数: 0

Abstract

Aim: Thyroid storm (TS) occurs in 10% of thyrotoxicosis patients and 1% of TS patients experience cardiogenic shock (CS), which is associated with poor prognosis. Methods: This is a single institution, retrospective study in which 56 patients with TS were evaluated. Results: BMI (p = 0.002), history of heart failure (OR 8.33 [1.91, 36.28]; p = 0.004), pro-BNP elevation (p = 0.04), chest x-ray showing interstitial edema (OR 3.33 [1.48, 7.52]; p = 0.01) and Burch-Wartofsky score (62.5 vs 40; p = 0.004) showed association with CS. CS patients had increased length of stay (16.5 vs 4 days; p = 0.01) and higher in-hospital mortality (OR 24.5 [2.90, 207.29]; p < 0.001). Conclusion: These risk factors are useful to risk stratify TS patients on admission, institute therapy in a timely manner and decrease mortality.

查看原文本刊更多论文

甲状腺风暴并发心源性休克的危险因素：一项回顾性和病例系列研究。

目的：甲状腺风暴（TS）发生在10%的甲状腺毒症患者中，1%的TS患者经历心源性休克（CS），这与预后不良有关。方法：这是一项单一机构的回顾性研究，对56例TS患者进行了评估。结果：BMI（p=0.002）、心力衰竭史（OR 8.33[1.91，36.28]；p=0.004）、前BNP升高（p=0.04）、胸部x光检查显示间质水肿（OR 3.33[1.48，7.52]；p=0.01）和Burch-Wartfsky评分（62.5 vs 40；p=0.004。CS患者的住院时间增加（16.5天vs 4天；p=0.01），住院死亡率增加（OR 24.5[2.90207.29]；p结论：这些风险因素有助于TS患者入院时的风险分层，及时进行治疗，降低死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.